Item 2.02 - Results of Operations and Financial Conditions and Item 8.01 - Other Events.

As previously announced, in December 2012, the Company's board of directors voted unanimously to implement a reverse split of the Company's outstanding common shares at the ratio of one-for-twelve (1:12), and the reverse split was approved by the Company's stockholders at a special meeting held on December 21, 2012. The reverse split became effective on December 28, 2012. All of the share amounts indicated in this filing have been adjusted to reflect the effect of this reverse split.

As of December 31, 2012, OXiGENE, Inc. expects to report cash, cash equivalents and restricted cash of approximately $5.0 million, compared with approximately $10.0 million at December 31, 2011.

In connection with OXiGENE's at-the-market offering agreement with MLV & Co. LLC, OXiGENE issued approximately 26,500 shares of common stock for proceeds of approximately $0.1 million, during the three months ended December 31, 2012.

In connection with OXiGENE's purchase agreement with Lincoln Park Capital Fund, LLC, OXiGENE issued approximately 66,500 shares of common stock for proceeds of approximately $0.4 million, during the three months ended December 31, 2012.

As of December 31, 2012 the Company had approximately 1,750,000 shares outstanding, compared to approximately 1,270,000 shares outstanding as of December 31, 2011.

---